Cerus Corp CERS
Cerus Corp (Nasdaq: CERS) is a hematology medical device company. Its next catalyst on record is INTERCEPT Red Blood Cells (RedeS study): Preliminary results from US Phase 3 RedeS study (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: INTERCEPT Red Blood Cells (RedeS study) — Preliminary results from US Phase 3 RedeS study (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| INTERCEPT Blood System - Platelets | Pathogen reduction of platelets | device-combination | NA_NON_THERAPEUTIC |
| INTERCEPT Blood System - Plasma | Pathogen reduction of plasma | device-combination | NA_NON_THERAPEUTIC |
| INTERCEPT Blood System - Cryoprecipitation (IFC) | Fibrinogen complex for bleeding with fibrinogen deficiency | device-combination | NA_NON_THERAPEUTIC |
| INTERCEPT Blood System - Red Blood Cells | Pathogen reduction of red blood cells | device-combination | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other hematology companies
- Haemonetics Corp HAE
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.